| pubmed-article:2970788 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2970788 | lifeskim:mentions | umls-concept:C0051696 | lld:lifeskim |
| pubmed-article:2970788 | lifeskim:mentions | umls-concept:C0340288 | lld:lifeskim |
| pubmed-article:2970788 | lifeskim:mentions | umls-concept:C0699826 | lld:lifeskim |
| pubmed-article:2970788 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:2970788 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:2970788 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:2970788 | pubmed:dateCreated | 1988-10-11 | lld:pubmed |
| pubmed-article:2970788 | pubmed:abstractText | This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris. The patients (n = 29) were evaluated during a 26-week single-blind dose titration phase followed by a 6-week double-blind placebo-randomized withdrawal phase. No patient withdrawals resulted from adverse events directly related to amlodipine. A comparison of the antianginal effects of amlodipine in the single-blind phase with the placebo phase showed a reduction in anginal episodes (p less than 0.001) and a decrease in sublingual nitroglycerin usage (p less than 0.01) that persisted in the treated double-blind group (n = 12). The place-bo double-blind group (n = 10) had a reduction in anginal episodes, but no significant change in sublingual nitroglycerin usage. The antiischemic effects of amlodipine were evident; there was an increase in exercise tolerance and a reduction of ST-segment depression, as seen in the 24-hour after-dose (range 23 to 30 hours) exercise tread-mill test. During single-blind therapy, total exercise time (p less than 0.001) and time to 1 mm ST depression (p less than 0.001) displayed an overall improvement. During the double-blind phase, the treated group demonstrated an improvement in total exercise time (p = 0.01) while the placebo group had no significant change. The total amount of ST depression also differed between treated and placebo groups (1.2 +/- 0.12 vs 1.8 +/- 0.17 mm, respectively, p less than 0.01). These results lend support to the clinical safety of this medication used as once-a-day therapy. | lld:pubmed |
| pubmed-article:2970788 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2970788 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2970788 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2970788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2970788 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2970788 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2970788 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2970788 | pubmed:issn | 0002-9149 | lld:pubmed |
| pubmed-article:2970788 | pubmed:author | pubmed-author:GlasserS PSP | lld:pubmed |
| pubmed-article:2970788 | pubmed:author | pubmed-author:WestT WTW | lld:pubmed |
| pubmed-article:2970788 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2970788 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2970788 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:2970788 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2970788 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2970788 | pubmed:pagination | 518-22 | lld:pubmed |
| pubmed-article:2970788 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:meshHeading | pubmed-meshheading:2970788-... | lld:pubmed |
| pubmed-article:2970788 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2970788 | pubmed:articleTitle | Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. | lld:pubmed |
| pubmed-article:2970788 | pubmed:affiliation | Division of Cardiology, University of South Florida College of Medicine, Tampa 33612. | lld:pubmed |
| pubmed-article:2970788 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2970788 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2970788 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2970788 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
